Merck & Co., Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 48.70B | 59.28B | 60.12B | 64.17B | 64.93B | 1.2% | |
| Cost of Revenue | (13.63B) | (17.41B) | (16.13B) | (15.19B) | (18.20B) | 19.8% | |
Gross Profit | 35.08B | 41.87B | 43.99B | 48.98B | 46.73B | -4.6% | |
| Operating Expenses | |||||||
| Research & Development | (12.24B) | (13.55B) | (30.53B) | (17.94B) | (12.51B) | -30.2% | |
| Selling, General & Administrative | (9.40B) | (9.67B) | (9.88B) | (10.10B) | (10.73B) | 6.2% | |
| Depreciation & Amortization | (3.21B) | (3.91B) | (3.87B) | (4.50B) | (5.84B) | 29.8% | |
Operating Income (EBIT) | 13.20B | 18.28B | 2.95B | 20.22B | 23.49B | 16.1% | |
| Non-Operating Items | |||||||
| Interest Income | 36.00M | 157.00M | 365.00M | 415.00M | 343.00M | -17.3% | |
| Interest Expense | (806.00M) | (962.00M) | (1.15B) | (1.27B) | (1.36B) | 6.8% | |
| Other Income/Expenses (Net) | 680.00M | -1.84B | -1.06B | -285.00M | -2.42B | 748.8% | |
Income Before Tax | 13.88B | 16.44B | 1.89B | 19.94B | 21.07B | 5.7% | |
| Income Tax Expense | (1.52B) | (1.92B) | (1.51B) | (2.80B) | (2.80B) | 0.0% | |
Net Income | 13.05B | 14.52B | 365.00M | 17.12B | 18.25B | 6.6% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $5 | $6 | $0 | $7 | $7 | 8.0% | |
| Weighted Avg Shares Outstanding | 2.53B | 2.53B | 2.61B | 2.53B | 2.50B | -1.2% | |
| Weighted Avg Shares Outstanding (Diluted) | 2.54B | 2.54B | 2.55B | 2.54B | 2.51B | -1.3% | |
EBITDA | 17.90B | 21.32B | 6.91B | 25.71B | 28.26B | 9.9% |
Explore MRK
MRK in the Healthcare
Mega Cap